Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A French multicentre prospective evaluation of resection margins in 150 evaluable specimens

HPB

Volumn 16, Issue 1, 2014, Pages 20-33

  Delpero, Jean Robert ^a   Bachellier, Philippe ^c   Regenet, Nicolas ^d   Le Treut, Yves Patrice ^b   Paye, François ^e   Carrere, Nicolas ^f   Sauvanet, Alain ^g   Autret, Aurélie ^a   Turrini, Olivier ^a   Monges Ranchin, Geneviève ^a   Boher, Jean Marie ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f UNIVERSITÉ DE TOULOUSE   (France)

^g BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PORTAL VEIN; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC VEIN; TERTIARY CARE CENTER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESENTERIC ARTERY, SUPERIOR; MESENTERIC VEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PORTAL VEIN; PROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890570576     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12061     Document Type: Article

References (70)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide. International Agency for Research on Cancer, Lyon, France. Available at http://globocan.iarc. fr/factsheet.asp (last accessed 12 June 2012)
2. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, et al. (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54: 385-387. (Pubitemid 40299095)
3. Shaib Y, Davila J, Naumann C, El-Serag H,. (2007) The impact of curative intent surgery on the survival of pancreatic cancer patients: a US population-based study. Am J Gastroenterol 102: 1377-1382. (Pubitemid 46976285)
4. Cartwright T, Richards DA, Boehm KA,. (2008) Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 15: 308-313.
5. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234: 758-768. (Pubitemid 33117196)
6. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277. (Pubitemid 46143304)
7. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4: 567-579.
8. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, et al. (2001) Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 5: 121-130. (Pubitemid 33652049)
9. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW,. (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91: 586-594. (Pubitemid 38624667)
10. Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, et al. (2004) Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 40: 549-558. (Pubitemid 38220772)
11. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, et al. (2006) A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to longterm survival in pancreatic cancer. J Gastrointest Surg 10: 1338-1345.
12. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, et al. (2008) Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 14: 5.
13. van den Broeck A, Sergeant G, Ectors N, van Steenbergen W, Aerts R, Topal B,. (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35: 600-604.
14. Fatima J, Schnelldorfer T, Barton J, Wood CM, Wiste HJ, Smyrk TC, et al. (2010) Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 145: 167-172.
15. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254: 311-319.
16. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, et al. (2012) Pancreatic ductal adenocarcinoma: longterm survival does not equal cure. Surgery 152 (Suppl.): 43-49.
17. Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP, et al. (2008) Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 207: 510-519.
18. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS,. (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB 11: 18-24.
19. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, et al. (2011) A prospective comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18: 2318-2328.
20. Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E,. (2012) R1 resection in pancreatic cancer has significant impact on longterm outcome in standardized pathology modified for routine use. Surgery 152 (Suppl.): 103-111.
21. Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Carpenter DH, et al. (2012) Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg 147: 753-760.
22. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246: 52-60. (Pubitemid 47012207)
23. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, et al. (2008) Pancreatic Cancer Meta-Analysis Group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143: 75-83. (Pubitemid 351159303)
24. Verbeke CS, Gladhaug IP,. (2012) Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 99: 1036-1049.
25. Buchler MW, Werner J, Weitz J,. (2010) R0 in pancreatic cancer surgery: surgery, pathology, biology, or definition matters? Ann Surg 251: 1011-1012.
26. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A,. (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93: 1232-1237. (Pubitemid 44547022)
27. Verbeke CS,. (2008) Resection margins and R1 rates in pancreatic cancer-are we there yet? Histopathology 52: 787-796. (Pubitemid 351724902)
28. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15: 1651-1660.
29. Verbeke CS, Menon KV,. (2009) Redefining resection margin status in pancreatic cancer. HPB 11: 282-289.
30. Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, et al. (2009) Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 55: 277-283.
31. Gaedcke J, Gunawan B, Grade M, Szöke R, Liersch T, Becker H, et al. (2010) The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg 395: 451-458.
32. Schlitter AM, Esposito I,. (2010) Definition of microscopic tumour clearance (R0) in pancreatic cancer resections. Cancers 2: 2001-2010.
33. Liszka Ł, Pajak J, Zielińska-Pajak E, Gołka D, Mrowiec S, Lampe P,. (2010) Different approaches to assessment of lymph nodes and surgical margin status in patients with ductal adenocarcinoma of the pancreas treated with pancreaticoduodenectomy. Pathology 42: 138-146.
34. Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ, et al. (2010) Positive mobilization margins alone do not influence survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 251: 1003-1010.
35. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308: 147-156.
36. Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C,. (2012) Pancreatic surgery for adenocarcinoma. Curr Opin Gastroenterol 8: 488-493.
37. Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L,. (2011) Standardization of surgical and pathologic variables is needed in multicentre trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol 18: 337-344.
38. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. (2010) AJCC Cancer Staging Manual, 7th edn. New York, NY: Springer.
39. Washington K, Berlin J, Branton P, Burgart LJ, Carter DK, Fitgibbons P, et al. (2012) Protocol for the Examination of Specimens From Patients with Carcinoma of the Exocrine Pancreas. Avalaible at http://www.cap.org/apps/docs/ committees/cancer/cancer-protocols/2012/PancreasExo-12protocol-3200.pdf (last accessed 30 June 2012)
40. National Comprehensive Cancer Network (NCCN). (2012) Clinical Practice Guidelines in Oncology, Pancreatic adenocarcinoma, Version 2. Available at http://www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf (last accessed 19 August 2012).
41. Michalski CW, Kleeff J, Wente MN, Diener MK, Büchler MW, Friess H,. (2007) Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 94: 265-273. (Pubitemid 46423842)
42. Campbell F, Bennett M, Foulis AJ,. (2002) Minimum Dataset for Histopathological Reporting of Pancreatic, Ampulla of Vater and Bile Duct Carcinoma. London: Royal College of Pathologists. Available at http://www.rcpath.org (last accessed 17 July 2012).
43. Hruban RH, Pitman MB, Klimstra D,. (2007) Tumors of the Pancreas. Washington, DC: Armed Forces Institute of Pathology.
44. Sobin LH, Gaspodarowicz MK, Wittekind C,. (2009) TNM Classification of Malignant Tumors, 7th edn. New York, NY: Wiley & Sons.
45. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Fernandez-Del Castillo C, Deshpande V, et al. (2012) Pancreatic ductal adenocarcinoma: is there a survival difference for r1 resections versus locally advanced unresectable tumors? What is a 'true' r0 resection? Ann Surg September 10, in press.
46. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. (2009) Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27: 2855-2862.
47. Staley CA, Cleary KR, Abbruzzese JL, Lee JE, Ames FC, Fenoglio CJ, et al. (1996) The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas 12: 373-380. (Pubitemid 26138631)
48. Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G,. (1998) The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 433: 237-242. (Pubitemid 28448679)
49. Chatelain D, Flejou JF,. (2002) Pancreatectomy for adenocarcinoma: prognostic factors, recommendations for pathological report. Ann Pathol 22: 422-431.
50. Compton CC, Henson DE,. (1997) Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med 121: 1129-1136.
51. Albores-Saavedra J, Heffess C, Hruban RH, Klimstra D, Longnecker D,. (1999) Recommendations for the reporting of pancreatic specimens containing malignant tumours. The Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 11: 304-307. (Pubitemid 29102737)
52. Torre ML, Nigri G, Ferrari L, Cosenza G, Ravaioli M, Ramacciato G,. (2012) Hospital volume, margin status, and longterm survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 78: 225-229.
53. Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, et al. (2012) Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16: 68-79.
54. Sanjay P, Takaori K, Govil S, Shrikhande SV, Windsor JA,. (2012) 'Artery-first' approaches to pancreatoduodenectomy. Br J Surg 99: 1027-1035.
55. Turrini O, Ewald J, Barbier L, Mokart D, Blache JL, Delpero JR,. (2012) Should portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg September 10. doi: 10.1097/SLA.0b013e318269d23c
56. Japan Pancreas Society. (2003) Classification of Pancreatic Cancer, 2nd edn. Tokyo: Kanehara.
57. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28: 219-230. (Pubitemid 38437313)
58. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. (2004) Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8: 935-949; discussion 949-950.
59. Barbier L, Turrini O, Grégoire E, Viret F, Le Treut YP, Delpero JR,. (2011) Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB 13: 64-69.
60. Verbeke CS, Knapp J, Gladhaug IP,. (2011) Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology 59: 1111-1121.
61. Wittekind C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P, et al. (2009) A uniform residual tumour (R) classification: integration of the R classification and the circumferential margin status. Cancer 115: 3483-3488.
62. Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, et al. (2012) Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Surgery 152 (Suppl.): 112-119.
63. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26: 3503-3510.
64. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, et al. (2009) The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13: 1337-1344.
65. Huebner M, Kendrick M, Reid-Lombardo KM, Que F, Therneau T, Qin R, et al. (2012) Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg 16: 920-926.
66. Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, et al. (2009) CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 13: 349-353.
67. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S,. (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10: 511-518. (Pubitemid 43619152)
68. Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL,. (2002) En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 6: 147-115.
69. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, et al. (2005) Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer 92: 1372-1381. (Pubitemid 40705002)
70. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496-3502.